Clinical Trial Update: Study Evaluating CMD-193 in Advanced Malignant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of CMD-193 in advanced malignant solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CMD-193

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED